Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:

Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY

H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat: Tuesday, September 9, 2025 at 8:00 a.m. Eastern Time in New York, NY

TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Fireside Chat: Thursday, September 18, 2025 at 1:40 p.m. Eastern Time (Virtual)

Live webcasts of each fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at acadia.com and follow us on LinkedIn and X.